Stay updated with breaking news from Static Physician. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
This new phase 4 data provides some valuable insights for healthcare professionals and those seeking to compare therapy options for psoriasis.
An open-label, efficacy assessor-blinded study comparing SKYRIZI® (risankizumab) to Otezla® (apremilast) for the treatment of adult patients with moderate...
AbbVie Inc (NYSE: ABBV) announced that the British Journal of Dermatology published results from the head-to-head Phase 4 IMMpulse study that evaluated the efficacy and safety of Skyrizi (risankizumab) compared to Amgen Inc's (NASDAQ:
/PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that new Otezla (apremilast) data, along with findings on the unmet need for patients with plaque...
/PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Otezla® (apremilast) for the treatment of...